Breast Cancer Ireland is delighted to support a new exciting Clinical Trial –The Shamrock Trial, that is focussing on HER2+ patients, with recurrence. This trial will use of a new 4th generation drug, Deruxtecan, combined with initial chemotherapy. After one month it is hoped to de-escalate the use of chemotherapy, continue with the drug and it is anticipated after 2-3 year period that we will see a 100% response rate in patients – a cure for this particular subtype.
Participation is key in clinical trials. Please speak to your medical team if you are interested in this or other clinical trials ongoing in Ireland.
For more information see www.cancertrials.ie